NYSE:EWMedical Equipment
Will Strong 10‑Year RESILIA Data and Higher 2026 Guidance Change Edwards Lifesciences' (EW) Narrative?
Edwards Lifesciences recently reported 10‑year results from its COMMENCE aortic trial, showing high freedom from valve deterioration and reoperation for patients treated with its RESILIA tissue, alongside first‑quarter 2026 sales of US$1,648.6 million and net income of US$380.7 million.
The new long‑term RESILIA data, combined with raised 2026 sales guidance of US$6.5 billion to US$6.9 billion, strengthens the clinical and commercial underpinnings of Edwards’ heart valve franchise.
We’ll now...